Welcome to our dedicated page for Avadel Pharmaceu SEC filings (Ticker: AVDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avadel Pharmaceuticals plc (Nasdaq: AVDL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. Avadel is an Ireland-incorporated biopharmaceutical company focused on sleep-related disorders, and its filings provide detailed information on its commercial product LUMRYZ, clinical programs, licensing arrangements and corporate transactions.
Investors can review Avadel’s Form 10-K annual reports and Form 10-Q quarterly reports for narrative and quantitative discussions of LUMRYZ net product revenue, patient uptake, research and development spending, and risk factors related to narcolepsy, idiopathic hypersomnia and broader business operations. Current reports on Form 8-K highlight material events such as the Transaction Agreement and subsequent amendment with Alkermes plc, the proposed court-sanctioned scheme of arrangement under Irish law, settlement and license agreements with Jazz Pharmaceuticals, and the exclusive global license for valiloxybate from XWPharma.
These filings also document key clinical and regulatory milestones, including the FDA approvals that made LUMRYZ the first and only once-at-bedtime oxybate for extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy, Orphan Drug Exclusivity grants, and the design and status of Phase 3 studies such as REST-ON and REVITALYZ. Transaction-related disclosures describe the structure, consideration and conditions of the proposed acquisition by Alkermes and the evaluation of alternative proposals under the Irish Takeover Rules.
On Stock Titan, each new AVDL filing from EDGAR is surfaced in real time and paired with AI-powered summaries that explain the main points in clear language. Users can quickly see which filings involve LUMRYZ clinical data, royalty and license agreements, or the Alkermes acquisition terms, and can drill down into the full text for deeper analysis. Insider ownership and compensation details, when disclosed in proxy materials and related documents, are also accessible through the SEC filings stream, helping investors build a comprehensive view of governance and incentives at Avadel.
Weiss Asset Management LP reported open-market sale transactions in this Form 4 filing.
Weiss Asset Management LP reported a full exit from its indirect stake in AVADEL PHARMACEUTICALS PLC in connection with the company’s acquisition by Alkermes plc. The filing shows 11,112,052 ordinary shares were converted into the right to receive $21.00 per share in cash, plus a contingent value right for an additional $1.50 in cash per share if a specified milestone is achieved. After this transaction, the filing reports 0 shares owned. The shares were held by two private investment funds managed by Weiss Asset Management, which disclaims beneficial ownership beyond its pecuniary interest.
Avadel Pharmaceuticals received a Form 3 indicating that Weiss Asset Management LP and Andrew Weiss are reporting as ten percent owners. The filing shows indirect beneficial ownership of 11,112,052 ordinary shares, held by two private investment funds managed by Weiss Asset Management. The reporting parties and related entities disclaim beneficial ownership except for their pecuniary interest.
Avadel Pharmaceuticals plc received an amended Schedule 13G from investment firm Two Seas Capital LP, its general partner Two Seas Capital GP LLC, and Sina Toussi. The filing states that, as of December 31, 2025, each reporting person beneficially owned 0 ordinary shares and represented 0% of the outstanding class.
The filing notes that the ordinary shares had previously been held by Two Seas Global (Master) Fund LP, for which Two Seas Capital LP served as investment manager, but the group now reports no voting or dispositive power over any Avadel shares and confirms ownership of less than 5% of the class.
Janus Henderson Group plc reports beneficial ownership of 1,823,865 ordinary shares of Avadel Pharmaceuticals plc, representing 1.9% of the share class as of 12/31/2025. The shares are held across various asset manager subsidiaries in managed client portfolios.
The Janus Henderson asset managers exercise shared voting and investment power over these 1,823,865 shares but have no sole voting or dispositive power. Economic benefits, including dividends and sale proceeds, belong to the underlying managed portfolios, and Janus Henderson disclaims ownership of those rights. No single managed portfolio holds more than 5% of Avadel’s ordinary shares.
Avadel Pharmaceuticals chief operating officer Susan Rodriguez reported the disposition of 300,000 stock options on February 12, 2026, when Avadel was acquired by Alkermes plc through an Irish court-approved scheme of arrangement.
Each option to buy Avadel ordinary shares at an exercise price of $9.59 was canceled and exchanged for cash equal to the difference between $21.00 and the option’s exercise price per share, plus a non‑transferable contingent value right offering a potential additional $1.50 per share if specified milestones are achieved.